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Over 45 million people in the US are currently infected with herpes simplex virus type 2 (HSV-2). 
HSV-2 is the main cause of genital herpes and the virus can remain latent, with reactivations leading 
to new lesions and viral shedding. Antiviral treatments do not cure the infection, so a vaccine is 
sought to both prevent infection (prophylactic vaccine) and limit viral reactivation in those already 
infected (therapeutic vaccine). Previous findings that strong CD8+ T-cell responses are important for 
viral control, and the knowledge that there are many viral components, or antigens, targeted by the 
immune system make a vaccine that is capable of recognizing multiple targets and eliciting a strong 
T-cell response desirable. This led Dr. Anna Wald of the Vaccine and Infectious Disease Division 
(VIDD), along with VIDD’s Dr. David Koelle and outside collaborators, to study the safety and 
immunogenicity of a polyvalent therapeutic vaccine, named HerpV, in HSV-2 seropositive patients. 
The vaccine is comprised of multiple components designed to work together to elicit both CD4+ and 
CD8+ T-cell responses. These include recombinant human heat shock protein Hsc70, multiple 
peptides containing HSV-specific complexes, and a saponin adjuvant isolated from the South 
American soap bark tree (QS-21), which has been shown to increase both antibody and B-cell 
responses in previous experimental uses. The study enrolled 35 seropositive participants, and over 
the course of the study no serious adverse events occurred. All participants who received HerpV and 
QS-21 showed vaccine-induced CD8+ T-cell responses, and most showed CD4+ responses as well. 
Additionally, these responses are achieved using lower concentrations of peptides than in previous 
clinical trails, indicating that the use of the heat shock protein and/or QS-21 creates a more robust 
immune response. 
The HerpV vaccine is the first candidate HSV-2 vaccine to show both CD4+ and CD8+ T-cell 
responses for a broad range of antigens.  Additionally, this is the first human study where a heat 
shock protein-based vaccine has demonstrated an immune response against viral antigens. Given 
these results, the researchers are planning a follow-up study to test the clinical efficacy of this 
vaccine regimen. 
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